File No. CT/97/22-DCG(I)

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

सत्यमेव जयते

File No. CT/22/000097

To,

M/s. Roche Products (India) Private Limited,
146 B, 166 A, Unit No 7, 8, 9, 8th floor, R city office,
R City Mall Lal Bahadur Shastri Marg,
Ghatkopar (West) Mumbai (India) – 400086.

Sir,

With reference to your application No GCT/CT04/FF/2022/33424 (GCT/97/22) dated 07-09-2022, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, "**A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study To Evaluate Patient Preference For Home administration Of Fixed-Dose Combination Of Pertuzumab And Trastuzumab For Subcutaneous Administration In Participants With Early Or Locally Advanced / Inflammatory Her2-Positive Breast Cancer"** , **Protocol no. MO43110, Version 1.0 dated 02/02/2022 with a total of up-to 12 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(ii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(ix) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xi) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

(xix) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=, ...
Date: 2023.06.16 10:53:41 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

File No. CT/97/22-DCG(I)

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s. Roche Products (India) Private Limited, 146 B, 166 A, Unit No 7, 8, 9, 8th floor, R city office, R City Mall, Lal Bahadur Shastri Marg, Ghatkopar (West) Mumbai (India) – 400086** to conduct clinical trial of the new drug or investigational new drug as per **Protocol no. MO43110, Version 1.0 dated 02/02/2022** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in Part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2023.06.16 10:53:50 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:
Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Pertuzumab-Trastuzumab Injection 600mg+ 600mg/10ml vial (PH FDC SC / Phesgo®) Pertuzumab-Trastuzumab Injection 1200mg+ 600mg/15ml vial (PH FDC SC / Phesgo®) Pertuzumab Injection 420mg/14ml (Perjeta®) Trastuzumab for Injection 150mg (Herceptin®/ Herclon®) Trastuzumab Emtansine for Injection 160mg (Kadcyla®)
Therapeutic class:	Antineoplastic agents, recombinant humanized IgG1 monoclonal antibodies Antineoplastic agent, recombinant humanized IgG1 monoclonal antibody HER2 dimerization inhibitor Antineoplastic agent Antibody drug conjugate antineoplastic agent
Dosage form:	Solution for subcutaneous injection Concentrate for solution for infusion Powder for concentrate for solution for infusion Sterile powder for concentrate for infusion solution

Composition:	Pertuzumab= 600 mg/ vial In-house specification Active Trastuzumab= 600 mg/ vial In-house specification Active rHuPH20= 2000 U/mL In-house specification Inactive L-Histidine= 4.40 mg/ vial USP-NF/Ph. Eur./JP Inactive L-Histidine Hydrochloride Monohydrate= 36.1 mg/ vialPh. Eur./JP Inactive α,α-Trehalose Dihydrate=397 mg/ vial USP-NF/Ph. Eur./JP Inactive Sucrose= 342 mg/ vial USP-NF/Ph. Eur./JP Inactive Polysorbate 20=4.00 mg/ vial USP-NF/Ph. Eur./JPE Inactive L-Methionine=14.9 mg/ vial USP-NF/Ph. Eur./JP Inactive Water for Injection= QS to 10 mL USP-NF/Ph. Eur./JP Inactive Pertuzumab= 1200 mg/ vial In-house specification Active Trastuzumab= 600 mg/ vial In-house specification Active rHuPH20= 2000 U/mL In-house specification Inactive L-Histidine= 6.75 mg/ vial USP-NF/Ph. Eur./JP Inactive L-Histidine Hydrochloride Monohydrate= 53.7 mg/ vial Ph. Eur./JP Inactive α,α-Trehalose Dihydrate=397 mg/ vial USP-NF/Ph. Eur./JP Inactive Sucrose= 685 mg/ vial USP-NF/Ph. Eur./JP Inactive Polysorbate 20= 6.00 mg/ vial USP-NF/Ph. Eur./JPE Inactive L-Methionine= 22.4 mg/ vial USP-NF/Ph. Eur./JP Inactive Water for Injection= QS to 15 mL USP-NF/Ph. Eur./JP Inactive Pertuzumab= 420 mg/vial In-House specification Active L-Histidine= 43.5 mg/vial USP/Ph. Eur. Inactive Glacial Acetic Acid= 9.2 mg/vial USP/Ph. Eur. Inactive Sucrose= 575.1 mg/vial NF/Ph. Eur. Inactive Polysorbate 20= 2.8 mg NF/Ph. Eur. Inactive Sterile Water for Injection 14.0 mL USP/Ph. Eur. Inactive Trastuzumab= 150 mg/vial In House Specification Active L-Histidine hydrochloride (monohydrate)= 3.50 mg/vial Ph. Eur. Inactive L-Histidine= 2.25 mg/vial Ph. Eur., U.S.P./NF Inactive α,α-Trehalose (dihydrate)= 141.9 mg/vial Ph. Eur., U.S.P., Any other pharmacopoeia Inactive Polysorbate 20= 0.63 mg/vial Ph. Eur., U.S.P., Inactive Water for injection= 0.0 q.s. to 6.25 ml/vial Ph. Eur., U.S.P Inactive Trastuzumab Emtansine= 171 mg/vial In House Specification Active Sucrose= 514.0 mg/vial Any other pharmacopoeia, E.P., J.P. Inactive Succinic Acid= 10.1 mg/vial Any other pharmacopoeia Inactive Sodium Hydroxide= 3.9 mg/vial Any other pharmacopoeia, E.P., J.P. Inactive Polysorbate 20= 1.7 mg/vial Any other pharmacopoeia, E.P., Inactive
Indications:	For patients with early or locally advanced/ inflammatory HER2-positive Breast Cancer

File No. CT/97/22-DCG(I)

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Max Institute of Cancer care, 2nd, 26A, Ring Rd, Vikram Vihar, Lajpat Nagar IV, Lajpat Nagar, New Delhi-110024	Institutional Ethics Committee, East Block, Service Floor, Office of Ethics Committee, Next to Conference Room, Max Super Speciality Hospital, Saket, (A Unit of Devki Devi Foundation) 2, Press Enclave Road, Saket, New Delhi-110017 ECR/110/Inst/DL/2013/RR-19	Dr. Pramod Kumar Julka
2.	Saifee Hospital, 15/17, Maharshi Karve Road, Opposite Charni Road Station, Mumbai-400004, Maharashtra	Saifee Hospital, Institutional Review Board, 15/17, Maharshi Karve Road, Opposite Charni Road Station, Mumbai-400004, Maharashtra ECR/159/Inst/MH/2013/RR-19	Dr. Maheboob Mahamud Basade
3.	Tata Medical Center, 14 MAR (EW), Newtown, Rajarhat, Kolkata-700160	Institutional Review Board, Tata Medical Center, 14 MAR (EW), Newtown, Rajarhat, Kolkata-700160 ECR/269/Inst/WB/2013/RR-19	Dr. Joydeep Ghosh

****